Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting

被引：0

作者：

Shah, Rajiv

Reck, Martin

Grohe, Christian

Christoph, Daniel Christian

Buchmeier, Eva Lotte

Saalfeld, Felix Carl

Frost, Nikolaj

Kopp, Hans-Georg

Faehling, Martin

Griesinger, Frank

Roeper, Julia

Hoffknecht, Petra

Kuon, Jonas

Luan, Jingting

Chesi, Paolo

Christopoulos, Petros

Thomas, Michael

机构：

[1] Heidelberg Univ Hosp, Dept Thorac Oncol, Heidelberg, Germany

[2] NCT Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany

[3] TLRC H, Heidelberg, Germany

[4] German Ctr Lung Res, Heidelberg, Germany

[5] German Ctr Lung Res DZL, Lungen Clin Grosshansdorf, Airway Res Ctr North ARCN, Grosshansdorf, Germany

[6] Evangel Lungenklin Berlin, Klin Pneumol, Berlin, Germany

[7] Evang Kliniken Essen Mitte, Dept Med Oncol, Essen, Germany

[8] Klinikum Stadt Koln gGmbH, Cologne, Germany

[9] Univ Hosp Dresden, Clin Internal Med 1, Dresden, Germany

[10] Charite Univ Med Berlin, Berlin, Germany

[11] Free Univ Berlin, Berlin, Germany

[12] Humboldt Univ, Berlin, Germany

[13] Berlin Inst Hlth, Berlin, Germany

[14] Klin Schillerhohe, Robert Bosch Ctr Tumorerkrankungen, Stuttgart, Germany

[15] Klinikum Esslingen GmbH, Dept Pneumol, Esslingen, Germany

[16] Univ Med Oldenburg, Univ Dept Internal Med Oncol, Pius Hosp, Dept Hematol & Oncol, Oldenburg, Germany

[17] Univ Klin Innere Med Onkol, PIUS Hosp Oldenburg, Oldenburg, Germany

[18] Franziskus Hosp Harderberg, Dept Oncol, Niels Stensen Kliniken, Georgsmarienhutte, Germany

[19] SLK Fachklin Lowenstein, Lowenstein, Germany

[20] Sapienza Univ Rome, Dept Med Oncol, Policlin Umberto 1, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8085

引用

页数：1

共 50 条

[31] Follow-up after fi rst-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort studydFLORA
Douma, L. H.
Hofman, M. M.
Zwierenga, F.
Zondervan, T. M. T.
Buma, A. I. G.
Schouwink, H.
Dumoulin, D. W.
Burgers, J. A.
Smesseim, I.
Aerts, J. G. J. V.
Gooijer, C. J. de
ESMO OPEN, 2025, 10 (02)
[32] CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC
Antonia, Scott J.
Gettinger, Scott N.
Goldman, Jonathan
Brahmer, Julie
Borghaei, Hossein
Chow, Laura Q.
Ready, Neal E.
Gerber, David E.
Juergens, Rosalyn
Shepherd, Frances
Laurie, Scott A.
Young, Tina
Geese, William J.
Agrawal, Shruti
Li, Xuemei
Hellmann, Matthew D.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S250 - S251
[33] Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial
Bylicki, Olivier
Guisier, Florian
Scherpereel, Arnaud
Daniel, Catherine
Swalduz, Aurelie
Grolleau, Emmanuel
Bernardi, Marie
Hominal, Stephane
Prevost, Jean Briac
Pamart, Guillaume
Marques, Marie Helene
Cloarec, Nicolas
Deshayes, Simon
Raimbourg, Judith
Veillon, Remi
Oulkhouir, Youssef
Valette, Clarisse Audigier
Subtil, Fabien
Chouaid, Christos
Greillier, Laurent
LUNG CANCER, 2024, 194
[34] Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma
Portalone, L
Antilli, A
Nunziati, F
Crispino, C
DeMarinis, F
Friggeri, L
Lombardi, A
LoRusso, V
Pronzato, P
Sambiasi, D
Signora, M
TUMORI JOURNAL, 2005, 91 (01): : 15 - 18
[35] Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naive essential thrombocythemia patients in a real-world setting
Ito, Tomoki
Hashimoto, Yoshinori
Tanaka, Yasuhiro
Nakaya, Aya
Fujita, Shinya
Satake, Atsushi
Nakanishi, Takahisa
Konishi, Akiko
Hotta, Masaaki
Yoshimura, Hideaki
Ishii, Kazuyoshi
Hashimoto, Akiko
Kondo, Toshinori
Omura, Hiromi
Shinzato, Isaku
Tanaka, Takayuki
Nomura, Shosaku
EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 103 (02) : 116 - 123
[36] Real-world Experience of Caplacizumab for Adolescents in the First-line Setting: Case Reports
Tran, Thuy B.
Boyce, Jennifer
Mitchell, Heather
Speaks, Jeron
Arnall, Justin R.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (08) : E1031 - E1034
[37] Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma
Parakh, Sagun
Randhawa, Manreet
Nguyen, Bella
Warburton, Lydia
Hussain, Mohammad Akhtar
Cebon, Jonathan
Millward, Michael
Yip, Desmond
Ali, Sayed
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (01) : 26 - 30
[38] Nivolumab for Malignant Mesothelioma: A Real-World Experience
Niki, M.
Yokoi, T.
Takahashi, R.
Mikami, K.
Shibata, E.
Nakajima, Y.
Negi, Y.
Ishigaki, H.
Tada, A.
Higashiyama, T.
Kamei, T.
Minami, T.
Kuribayashi, K.
Kijima, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S758 - S758
[39] Real-world treatment for malignant pleural mesothelioma: the Belgian experience
Rosskamp, M.
Van Damme, N.
De Schutter, H.
Slabbaert, M.
Henau, K.
Praet, M.
Nackaerts, K.
Van Meerbeeck, J. P.
EUROPEAN JOURNAL OF CANCER, 2017, 72 : S177 - S178
[40] First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting
Dennen, Syvart
Harton, Joanna
Cockrum, Paul
Kim, George P.
MacEwan, Joanna P.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →